Parasuraman, Sudha
Novartis Pharmaceuticals Corporation, East Hanover, NJ
4 papers on CoChat
Most cited papers
- Verified
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research
Neuroblastoma Research and TreatmentsNeurofibromatosis and Schwannoma Cases
Cited by 394
- Verified
A phase 1b/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: Early encouraging clinical activity.
Sosman, J. A., Kittaneh, M., Lolkema, M. P. J. K., Postow, M. A., Schwartz, G., Franklin, C., Matano, A., Bhansali, S., Parasuraman, S., & Kim, K. (2014) · Journal of Clinical Oncology
Melanoma and MAPK PathwaysCutaneous Melanoma Detection and Management
Cited by 129
- Verified
Abstract PR02: LEE011: An orally bioavailable, selective small molecule inhibitor of CDK4/6– Reactivating Rb in cancer.
Kim, S., Loo, A., Chopra, R., Caponigro, G., Huang, A., Vora, S., Parasuraman, S., Howard, S., Keen, N., Sellers, W., et al. (2013) · Molecular Cancer Therapeutics
Advanced Breast Cancer TherapiesCancer-related Molecular Pathways
Cited by 106
- Verified
Abstract A276: Phase 1 multicenter, open label, dose-escalation study of LEE011, an oral inhibitor of cyclin-dependent kinase 4/6, in patients with advanced solid tumors or lymphomas.
Infante, J. R., Shapiro, G. I., Witteveen, P. O., Gerecitano, J. F., Ribrag, V., Chugh, R., Chakraborty, A., Matano, A., Zhao, X., Parasuraman, S., et al. (2013) · Molecular Cancer Therapeutics
Advanced Breast Cancer TherapiesCancer-related Molecular Pathways
Cited by 16
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free